Sector Expert: Megan McCloskey Dow

MLV & Co



Recent Quotes

"We reiterate our Buy recommendation for GALE."

— Megan McCloskey Dow, MLV & Co (11/13/12)
more >

"New data lends more support to the clinical potential of GALE's NeuVax."

— Megan McCloskey Dow, MLV & Co (10/26/12)
more >

"We are initiating coverage of GALE with a Buy rating."

— Megan McCloskey Dow, MLV & Co (10/24/12)
more >

"IMUC's ICT-107 data show immune response to broader glioma antigens."

— Megan McCloskey Dow, MLV & Co (6/4/12)
more >

"IMUC is committed to growing its pipeline."

— Megan McCloskey Dow, MLV & Co (5/25/12)
more >

"We are initiating coverage on IMUC, which has promising results from a phase 1 trial of ICT-107."

— Megan McCloskey Dow, MLV & Co (5/15/12)
more >



Due to permission requirements, not all quotes are shown.